Arunima Misra

Dec 5, 2024 | digitalcommons.library.tmc.edu | Biykem Bozkurt |Ajith Nair |Arunima Misra |Claire Scott

Keywordsneprilysin, neprilysin inhibitor, NEP inhibitor, angiotensin receptor–neprilysin inhibitor, ARNi, heart failure, sacubitril, sacubitril/valsartanAbstractThis article provides a contemporary review and a new perspective on the role of neprilysin inhibition in heart failure (HF) in the context of recent clinical trials and addresses potential mechanisms and unanswered questions in certain HF patient populations.

Dec 5, 2024 | digitalcommons.library.tmc.edu | Aliza Hussain |Arunima Misra |Biykem Bozkurt

AbstractHeart failure (HF) is a major health problem worldwide. The development of effective drug and/or device therapy is crucial to mitigate the significant morbidity, mortality and healthcare costs associated with HF. The choice of endpoint in clinical trials has important practical and clinical implications. Outcomes of interest including mortality and HF hospitalisations provide robust evidence for regulatory approval granted there is sufficiency of safety data.